Literature DB >> 23864457

Ischemic skin necrosis following terlipressin therapy: report of two cases and review of the literature.

Türker Taşliyurt1, Faruk Kutlutürk, Fikret Erdemır, Berna Murat Yelken, Abdulkerim Yilmaz, Bünyamin Kisacik, Pelin Aytan, Reşit Doğan Köseoğlu.   

Abstract

Terlipressin is a synthetic vasopressin analogue that is used in the treatment of bleeding esophageal varices and hepatorenal syndrome in patients with cirrhosis. Hepatorenal syndrome is a form of renal failure seen in patients with cirrhosis, with fatal outcomes. Ischemic adverse effects related to terlipressin are rarely observed. Herein, two cases who developed ischemic skin necrosis due to terlipressin usage are presented. Terlipressin therapy was started in two cirrhotic patients with presumptive hepatorenal syndrome. During the therapy, ecchymotic and necrotic changes were observed on the scrotal regions of both patients. Skin lesions were relieved after terlipressin therapy. Biopsy results were consistent with ischemia. Even if seen rarely, possible emergence of ischemic complications must be considered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23864457

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  2 in total

1.  Practice guidance for the use of terlipressin for liver cirrhosis-related complications.

Authors:  Xingshun Qi; Zhaohui Bai; Qiang Zhu; Gang Cheng; Yu Chen; Xiaowei Dang; Huiguo Ding; Juqiang Han; Lei Han; Yingli He; Fanpu Ji; Hongxu Jin; Bimin Li; Hongyu Li; Yiling Li; Zhiwei Li; Bang Liu; Fuquan Liu; Lei Liu; Su Lin; Dapeng Ma; Fanping Meng; Ruizhao Qi; Tianshu Ren; Lichun Shao; Shanhong Tang; Yufu Tang; Yue Teng; Chunhui Wang; Ran Wang; Yunhai Wu; Xiangbo Xu; Ling Yang; Jinqiu Yuan; Shanshan Yuan; Yida Yang; Qingchun Zhao; Wei Zhang; Yongping Yang; Xiaozhong Guo; Weifen Xie
Journal:  Therap Adv Gastroenterol       Date:  2022-05-18       Impact factor: 4.802

2.  Terlipressin-induced ischaemic skin necrosis.

Authors:  Anand V Kulkarni; Pramod Kumar; Nagaraj P Rao; Nageshwar Reddy
Journal:  BMJ Case Rep       Date:  2020-01-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.